Healthcare provider profile · identity verified

Vincent Oyler, MD

Allopathic & Osteopathic Physicians|Family Medicine · TYLER, TX · NPI 1194174979

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Vincent Oyler, MD received $65.42 in general payments during 2025 across 4 reported records.

Novartis Pharmaceuticals Corporation accounted for 50.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$65.42

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novartis Pharmaceuticals Corporation	Unresolved — no canonical attribution shown	$32.89	50.3%	2	2025
Dexcom, Inc.	Unresolved — no canonical attribution shown	$17.70	27.1%	1	2025
Medtronic, Inc.	Medtronic, Inc. exact · evidence 2025-07-22	$14.83	22.7%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$65.42	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
LEQVIO Normalized: leqvio	Drug	Novartis Pharmaceuticals Corporation	$32.89	2	2025
Source payment records 2025-02-10 · Novartis Pharmaceuticals Corporation · $15.69 · Open Payments source 2025-07-07 · Novartis Pharmaceuticals Corporation · $17.20 · Open Payments source
Dexcom G6 Transmitter Normalized: dexcom g6 transmitter	Medical Supply	Dexcom, Inc.	$17.70	1	2025
Source payment records 2025-11-05 · Dexcom, Inc. · $17.70 · Open Payments source
MINIMED 780G Normalized: minimed 780g	Device	Medtronic, Inc.	$14.83	1	2025
Source payment records 2025-10-16 · Medtronic, Inc. · $14.83 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference	2025	ENTRESTO open payments reported associated product	CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797	Entresto · 2024 Exact normalized brand match · 1 Part D row	18	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	856	146
Amlodipine Besylate	Amlodipine Besylate	631	126
Atorvastatin Calcium	Atorvastatin Calcium	602	108
Furosemide	Furosemide	542	95
Lisinopril	Lisinopril	438	81
Losartan Potassium	Losartan Potassium	414	92
Omeprazole	Omeprazole	409	85
Eliquis	Apixaban	337	42
Gabapentin	Gabapentin	330	53
Tamsulosin Hcl	Tamsulosin Hcl	310	54
Simvastatin	Simvastatin	304	63
Metoprolol Succinate	Metoprolol Succinate	294	55
Pantoprazole Sodium	Pantoprazole Sodium	289	58
Potassium Chloride	Potassium Chloride	282	58
Rosuvastatin Calcium	Rosuvastatin Calcium	278	69
Metformin Hcl	Metformin Hcl	244	53
Hydrochlorothiazide	Hydrochlorothiazide	237	46
Tramadol Hcl	Tramadol Hcl	230	48
Metoprolol Tartrate	Metoprolol Tartrate	226	44
Famotidine	Famotidine	179	31
Carvedilol	Carvedilol	174	35
Allopurinol	Allopurinol	165	33
Sertraline Hcl	Sertraline Hcl	156	32
Montelukast Sodium	Montelukast Sodium	148	39
Prednisone	Prednisone	147	79
Clopidogrel	Clopidogrel Bisulfate	134	25
Atenolol	Atenolol	126	23
Cephalexin	Cephalexin	116	67
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	114	34
Quetiapine Fumarate	Quetiapine Fumarate	107	13
Ipratropium Bromide	Ipratropium Bromide	101	82
Doxycycline Hyclate	Doxycycline Hyclate	100	84
Donepezil Hcl	Donepezil Hcl	99	15
Escitalopram Oxalate	Escitalopram Oxalate	98	20
Jardiance	Empagliflozin	97	17
Metformin Hcl Er	Metformin Hcl	94	21
Mirtazapine	Mirtazapine	94	20
Spironolactone	Spironolactone	93	21
Lorazepam	Lorazepam	91	22
Duloxetine Hcl	Duloxetine Hcl	87	18
Finasteride	Finasteride	85	16
Ezetimibe	Ezetimibe	82	18
Methylprednisolone	Methylprednisolone	82	77
Citalopram Hbr	Citalopram Hydrobromide	81	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	77	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	75	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	72	12
Jantoven	Warfarin Sodium	70	14
Olanzapine	Olanzapine	69	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	68	suppressed
Fluticasone Propionate	Fluticasone Propionate	65	16
Ropinirole Hcl	Ropinirole Hcl	65	12
Baclofen	Baclofen	63	suppressed
Meloxicam	Meloxicam	63	14
Clonazepam	Clonazepam	59	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	58	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	56	13
Latanoprost	Latanoprost	56	11
Pravastatin Sodium	Pravastatin Sodium	55	12
Venlafaxine Hcl Er	Venlafaxine Hcl	53	suppressed
Digoxin	Digoxin	52	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	51	21
Aripiprazole	Aripiprazole	51	suppressed
Azithromycin	Azithromycin	51	39
Sucralfate	Sucralfate	51	15
Trazodone Hcl	Trazodone Hcl	51	13
Memantine Hcl	Memantine Hcl	50	suppressed
Propranolol Hcl	Propranolol Hcl	49	suppressed
Trulicity	Dulaglutide	48	suppressed
Ozempic	Semaglutide	47	suppressed
Pregabalin	Pregabalin	47	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	46	suppressed
Buspirone Hcl	Buspirone Hcl	43	suppressed
Fentanyl	Fentanyl	43	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	43	suppressed
Alendronate Sodium	Alendronate Sodium	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Levetiracetam	Levetiracetam	41	suppressed
Warfarin Sodium	Warfarin Sodium	41	suppressed
Bumetanide	Bumetanide	40	suppressed
Ondansetron Odt	Ondansetron	38	23
Ciprofloxacin Hcl	Ciprofloxacin Hcl	37	28
Divalproex Sodium	Divalproex Sodium	37	suppressed
Labetalol Hcl	Labetalol Hcl	36	suppressed
Lacosamide	Lacosamide	36	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	35	suppressed
Fenofibrate	Fenofibrate	35	suppressed
Raloxifene Hcl	Raloxifene Hcl	35	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	35	24
Hydralazine Hcl	Hydralazine Hcl	34	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	suppressed
Nyamyc	Nystatin	34	16
Verapamil Er	Verapamil Hcl	34	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	33	33
Tizanidine Hcl	Tizanidine Hcl	33	11
Topiramate	Topiramate	33	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	suppressed
Amiodarone Hcl	Amiodarone Hcl	32	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	32	suppressed
Cefdinir	Cefdinir	32	31
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	32	suppressed
Levofloxacin	Levofloxacin	32	28
Myrbetriq	Mirabegron	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Terazosin Hcl	Terazosin Hcl	30	suppressed
Glipizide	Glipizide	29	suppressed
Xarelto	Rivaroxaban	29	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	28	suppressed
Dilt-Xr	Diltiazem Hcl	27	suppressed
Methenamine Hippurate	Methenamine Hippurate	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Nystatin	Nystatin	26	13
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Calcitriol	Calcitriol	25	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Lamotrigine	Lamotrigine	25	suppressed
Alprazolam	Alprazolam	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Midodrine Hcl	Midodrine Hcl	24	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	24	suppressed
Paliperidone Er	Paliperidone	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Fluconazole	Fluconazole	23	14
Levalbuterol Hcl	Levalbuterol Hcl	23	suppressed
Rexulti	Brexpiprazole	23	suppressed
Rytary	Carbidopa/Levodopa	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	22
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Clindamycin Hcl	Clindamycin Hcl	22	14
Lansoprazole	Lansoprazole	22	suppressed
Zenpep	Lipase/Protease/Amylase	22	suppressed
Glipizide Er	Glipizide	21	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	21	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	20	suppressed
Novolog Flexpen	Insulin Aspart	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	14
Cilostazol	Cilostazol	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Leflunomide	Leflunomide	19	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Lithium Carbonate	Lithium Carbonate	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Ceftriaxone	Ceftriaxone Sodium	17	14
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	17	suppressed
Timolol Maleate	Timolol Maleate	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Colesevelam Hcl	Colesevelam Hcl	16	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	16	suppressed
Lidocaine Hcl	Lidocaine Hcl	16	13
Methotrexate	Methotrexate Sodium	16	suppressed
Metolazone	Metolazone	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Bupropion Hcl	Bupropion Hcl	15	suppressed
Folic Acid	Folic Acid	15	suppressed
Nabumetone	Nabumetone	15	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Primidone	Primidone	14	suppressed
Propranolol Hcl Er	Propranolol Hcl	14	suppressed
Risperidone	Risperidone	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Glyburide	Glyburide	13	suppressed
Nitroglycerin	Nitroglycerin	13	11
Shingrix	Varicella-Zoster Ge/As01b/Pf	13	suppressed
Tiadylt Er	Diltiazem Hcl	13	suppressed
Amantadine	Amantadine Hcl	12	suppressed
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Enulose	Lactulose	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Probenecid-Colchicine	Probenecid/Colchicine	12	suppressed
Rivastigmine	Rivastigmine	12	suppressed
Ulticare Safety Pen Needle	Pen Needle, Diabetic, Safety	12	suppressed
Valsartan	Valsartan	12	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	11	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	11	suppressed
Clonidine	Clonidine	11	suppressed
Imipramine Hcl	Imipramine Hcl	11	suppressed
Insulin Aspart Flexpen	Insulin Aspart	11	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Nystop	Nystatin	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed
Repatha Sureclick	Evolocumab	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$65.42 · 4 records	Novartis Pharmaceuticals Corporation	Dexcom G6 Transmitter, LEQVIO, MINIMED 780G	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error